These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 30275568)

  • 1. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.
    Ruella M; Xu J; Barrett DM; Fraietta JA; Reich TJ; Ambrose DE; Klichinsky M; Shestova O; Patel PR; Kulikovskaya I; Nazimuddin F; Bhoj VG; Orlando EJ; Fry TJ; Bitter H; Maude SL; Levine BL; Nobles CL; Bushman FD; Young RM; Scholler J; Gill SI; June CH; Grupp SA; Lacey SF; Melenhorst JJ
    Nat Med; 2018 Oct; 24(10):1499-1503. PubMed ID: 30275568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resisting CAR T-cell Therapy: A Case Study.
    Cancer Discov; 2018 Dec; 8(12):1499-1500. PubMed ID: 30366924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
    Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
    Braendstrup P; Levine BL; Ruella M
    Cytotherapy; 2020 Feb; 22(2):57-69. PubMed ID: 32014447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
    Makita S; Yoshimura K; Tobinai K
    Cancer Sci; 2017 Jun; 108(6):1109-1118. PubMed ID: 28301076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
    Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.
    Song MK; Park BB; Uhm JE
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31658644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
    Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
    Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
    Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
    Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts.
    Quintarelli C; Guercio M; Manni S; Boffa I; Sinibaldi M; Di Cecca S; Caruso S; Abbaszadeh Z; Camera A; Cembrola B; Ciccone R; Orfao A; Martin-Martin L; Gutierrez-Herrero S; Herrero-Garcia M; Cazzaniga G; Nunes V; Songia S; Marcatili P; Marin FI; Ruella M; Bertaina V; Vinti L; Del Bufalo F; Algeri M; Merli P; De Angelis B; Locatelli F
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34135100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
    Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
    Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.
    Myers RM; Devine K; Li Y; Lawrence S; Leahy AB; Liu H; Vernau L; Callahan C; Baniewicz D; Kadauke S; McGuire R; Wertheim GB; Kulikovskaya I; Gonzalez VE; Fraietta JA; DiNofia AM; Hunger SP; Rheingold SR; Aplenc R; June CH; Grupp SA; Wray L; Maude SL
    Blood Adv; 2024 May; 8(9):2182-2192. PubMed ID: 38386999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
    Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
    Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What CAR Will Win the CD19 Race?
    Quintás-Cardama A
    Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
    Torikai H; Reik A; Liu PQ; Zhou Y; Zhang L; Maiti S; Huls H; Miller JC; Kebriaei P; Rabinovich B; Lee DA; Champlin RE; Bonini C; Naldini L; Rebar EJ; Gregory PD; Holmes MC; Cooper LJ
    Blood; 2012 Jun; 119(24):5697-705. PubMed ID: 22535661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
    Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
    Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.